Recent in vivo and in vitro results suggest that targeting CD47 with combinations including sorafenib results in a beneficial effect on patients with HCC.172 However, the effective use immunotherapy in HCC must fully consider the HCC-specific immune microenvironment and response. Here, CD47 is linked to hepatocellular carcinoma.